Jack Pollard

7.7k total citations · 2 hit papers
25 papers, 4.5k citations indexed

About

Jack Pollard is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Jack Pollard has authored 25 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 10 papers in Molecular Biology and 7 papers in Cancer Research. Recurrent topics in Jack Pollard's work include Cancer Genomics and Diagnostics (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Cancer, Hypoxia, and Metabolism (3 papers). Jack Pollard is often cited by papers focused on Cancer Genomics and Diagnostics (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Cancer, Hypoxia, and Metabolism (3 papers). Jack Pollard collaborates with scholars based in United States, France and Germany. Jack Pollard's co-authors include Jeff Green, Stuart Tugendreich, A. Krämer, Joon Sang Lee, Bartholomew J. Naughton, Mugdha Khaladkar, Andrew R. Leach, Yong Wang, Edgardo A. Ferrán and Melissa G. Mendez and has published in prestigious journals such as Bioinformatics, PLoS ONE and Nature Reviews Drug Discovery.

In The Last Decade

Jack Pollard

23 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Causal analysis approaches in Ingenuity Pathway Analysis

2013 3.9k citations A. Krämer, Jeff Green et al. Bioinformatics profile →
Applications of single-cell RNA sequencing in drug discovery and development

2023 205 citations Bram Van de Sande, Joon Sang Lee et al. Nature Reviews Drug Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jack Pollard United States	12	2.3k	797	727	606	460	25	4.5k
Jeff Green United States	9	2.1k 0.9×	617 0.8×	642 0.9×	429 0.7×	459 1.0×	24	4.2k
Edward Y. Chen United States	12	3.4k 1.5×	830 1.0×	763 1.0×	531 0.9×	466 1.0×	15	5.5k
Christopher M. Tan United States	18	3.8k 1.6×	803 1.0×	843 1.2×	591 1.0×	628 1.4×	40	6.1k
Weijun Luo United States	16	2.7k 1.2×	755 0.9×	702 1.0×	465 0.8×	640 1.4×	35	4.5k
Pengfei Li China	39	2.5k 1.1×	1.3k 1.6×	688 0.9×	346 0.6×	319 0.7×	214	4.8k
Li Cao China	27	2.0k 0.9×	441 0.6×	1.0k 1.4×	622 1.0×	748 1.6×	189	4.5k
Mikhail G. Dozmorov United States	36	2.2k 0.9×	708 0.9×	722 1.0×	567 0.9×	246 0.5×	153	4.0k
Jason Montojo Canada	6	3.1k 1.4×	897 1.1×	602 0.8×	572 0.9×	322 0.7×	7	5.0k
Simon Koplev United States	14	4.0k 1.7×	1.2k 1.5×	1.1k 1.5×	690 1.1×	548 1.2×	18	6.6k
Khalid Zuberi Canada	8	3.6k 1.5×	1.0k 1.3×	620 0.9×	578 1.0×	324 0.7×	8	5.4k

Countries citing papers authored by Jack Pollard

Since Specialization

Citations

This map shows the geographic impact of Jack Pollard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jack Pollard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jack Pollard more than expected).

Fields of papers citing papers by Jack Pollard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jack Pollard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jack Pollard. The network helps show where Jack Pollard may publish in the future.

Co-authorship network of co-authors of Jack Pollard

This figure shows the co-authorship network connecting the top 25 collaborators of Jack Pollard. A scholar is included among the top collaborators of Jack Pollard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jack Pollard. Jack Pollard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sande, Bram Van de, Joon Sang Lee, Euphemia Mutasa-Gottgens, et al.. (2023). Applications of single-cell RNA sequencing in drug discovery and development. Nature Reviews Drug Discovery. 22(6). 496–520. 205 indexed citations breakdown →

Camps, J., Floriane Noël, Robin Liechti, et al.. (2022). Meta-Analysis of Human Cancer Single-Cell RNA-Seq Datasets Using the IMMUcan Database. Cancer Research. 83(3). 363–373. 20 indexed citations

Calvet, Loreley, Emmanuel Spanakis, Jean-Christophe Le Bail, et al.. (2022). YAP1 is essential for malignant mesothelioma tumor maintenance. BMC Cancer. 22(1). 639–639. 12 indexed citations

Pomponio, Robert J., Anne Caron, Joachim Theilhaber, et al.. (2022). An integrative approach of digital image analysis and transcriptome profiling to explore potential predictive biomarkers for TGFβ blockade therapy. Acta Pharmaceutica Sinica B. 12(9). 3594–3601. 9 indexed citations

Shomali, Maysoun, Zhuyan Guo, Jane Cheng, et al.. (2022). Abstract P4-02-08: Amcenestrant in combination with CDK4/6 inhibitor palbociclib demonstrates synergistic anti-tumor activity in ER+ endocrine-resistant breast cancer xenograft models. Cancer Research. 82(4_Supplement). P4–2. 2 indexed citations

Tolstykh, Tatiana, Yuan Zhang, Dinesh S. Bangari, et al.. (2021). An experimental model of anti-PD-1 resistance exhibits activation of TGFß and Notch pathways and is sensitive to local mRNA immunotherapy. OncoImmunology. 10(1). 1881268–1881268. 20 indexed citations

Spanakis, Emmanuel, Loreley Calvet, Colette Dib, et al.. (2021). Abstract 2161: A transcriptomic signature for measuring YAP1 activity in patient samples and tumor models. Cancer Research. 81(13_Supplement). 2161–2161. 2 indexed citations

Shomali, Maysoun, Fangxian Sun, Laurent Besret, et al.. (2021). Abstract 739: Preclinical and clinical activity of SAR439859, Amcenestrant, a next generation SERD. Cancer Research. 81(13_Supplement). 739–739.

Calvet, Loreley, Emmanuel Spanakis, Isabelle Sanchez, et al.. (2020). Abstract 4858: Oncogenic HIPPO-YAP1: in vivo target validation of YAP1 in malignant mesothelioma. Cancer Research. 80(16_Supplement). 4858–4858. 1 indexed citations

10.

Malkova, Natalia V., Tatiana Tolstykh, Mikhail Levit, et al.. (2020). Abstract 4451: Combination of local mRNA immunotherapy with systemic immune checkpoint blockade demonstrates anti-tumor activity across a diverse range of preclinical syngeneic tumor models. Cancer Research. 80(16_Supplement). 4451–4451. 2 indexed citations

11.

Theilhaber, Joachim, et al.. (2020). Construction and optimization of gene expression signatures for prediction of survival in two-arm clinical trials. BMC Bioinformatics. 21(1). 333–333. 2 indexed citations

12.

Gregory, Richard C., Rita Greco, Hongjing Qu, et al.. (2018). Abstract 2790: The anti-TGFβ neutralizing antibody, SAR439459, blocks the immunosuppressive effects of TGFβ and inhibits the growth of syngeneic tumors in combination with anti-PD1. Cancer Research. 78(13_Supplement). 2790–2790. 3 indexed citations

13.

Theilhaber, Joachim, Stephen F. Madden, Sherry Cao, et al.. (2018). Abstract 5550: Translational biomarkers for SAR439459, an anti-TGFβ antibody for cancer immunotherapy. Cancer Research. 78(13_Supplement). 5550–5550. 1 indexed citations

14.

Lampa, Michael, Heike Arlt, Timothy He, et al.. (2017). Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition. PLoS ONE. 12(9). e0185092–e0185092. 119 indexed citations

15.

Chiron, Marielle, Rebecca G. Bagley, Jack Pollard, et al.. (2014). Differential Antitumor Activity of Aflibercept and Bevacizumab in Patient-Derived Xenograft Models of Colorectal Cancer. Molecular Cancer Therapeutics. 13(6). 1636–1644. 56 indexed citations

16.

Wang, Anlai, Rita Greco, Zhifang Li, et al.. (2014). Combination of PIM and JAK2 inhibitors synergistically suppresses cell proliferation and overcomes drug resistance of myeloproliferative neoplasms. Oncotarget. 5(10). 3362–3374. 24 indexed citations

17.

Theilhaber, Joachim, Sanjay N. Rakhade, Nayantara Kothari, et al.. (2013). Gene Expression Profiling of a Hypoxic Seizure Model of Epilepsy Suggests a Role for mTOR and Wnt Signaling in Epileptogenesis. PLoS ONE. 8(9). e74428–e74428. 33 indexed citations

18.

Krämer, A., Jeff Green, Jack Pollard, & Stuart Tugendreich. (2013). Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics. 30(4). 523–530. 3879 indexed citations breakdown →

19.

Chiron, Marielle, Rebecca G. Bagley, Jack Pollard, et al.. (2013). Abstract B2: Switching to aflibercept treatment resulted in greater tumor responses than continuous bevacizumab treatment in patient-derived xenograft models of colorectal cancer.. Molecular Cancer Therapeutics. 12(11_Supplement). B2–B2. 2 indexed citations

20.

Pollard, Jack, et al.. (2005). A Computational Model to Define the Molecular Causes of Type 2 Diabetes Mellitus. Diabetes Technology & Therapeutics. 7(2). 323–336. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact